Europe is accounted to have the second highest share in the market owing to increasing awareness about the renal diseases.
Kidney diseases are due to improper functioning of the kidneys and associated renal system over a longer period of time because of its high incidence of Diabetic cases, and high blood pressure. Kidneys have numerous functions, such as maintaining a balance of water and minerals, such as potassium, sodium, and phosphorus in the blood, remove waste by-products from the blood after digestion, muscle activity, and exposure to chemicals or medications. When any form of damage to the kidney occurs, they ultimately lose their vital function, which is fatal.
Europe Renal Disease Therapeutics Market was worth $ x.xx billion in 2018 and estimated to reach $ x.xx billion by the end of 2023 with a CAGR of x.xx %.
Europe Renal Disease Therapeutics Market is primarily driven by growing aging population, increasing number of individuals with insurance due to the Affordable Care Act, Increasing Diabetic Population, growing awareness of both acute and chronic kidney disease, and growing demand for the advanced diagnostics and therapeutics for the disease. Disparities of Renal Transplant Therapy, expiring of patents of some of the branded drugs for the late stage CKD and changing reimbursement scenario in some of the major countries, Negative Societal Effects are the factors hindering the growth of the market.
The Europe Renal Disease Therapeutics market is segmented based on the Application, and treatment. Application mode is segmented into Kidney Stone Disease, End-Stage Kidney Disease, Kidney Failure, Chronic Kidney Disease, Hypertension, Diabetes, and Anaemia. The treatment segment is further categorized into Dialysis Equipment, Renal Denervation devices, Wearable artificial kidney device, and distal embolic protection devices. On the basis of geography, the Europe Renal Disease Therapeutics market is analyzed under various regions namely U.K, Germany, France, Italy, and Spain.
Some of the key players influencing the Europe Renal disease Therapeutics market are Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Hoffmann-La Roche Inc., Shire Inc., Fresenius Medical Care, Baxter International, Davita Healthcare Partners.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Introduction
5.1.2 Kidney Stone Disease
5.1.3 End-Stage Kidney Disease
5.1.4 Kidney Failure
5.1.5 Chronic Kidney Disease
5.1.6 Hypertension
5.1.7 Diabetes
5.1.8 Anaemia
5.1.4 Y-o-Y Growth Analysis, By Application
5.1.5 Market Attractiveness Analysis, By Application
5.1.6 Market Share Analysis, By Application
5.2 Treatment devices
5.2.1 Introduction
5.2.2 Dialysis Equipment
5.2.3 Renal Denervation devices
5.2.4 Wearable artificial kidney device
5.2.5 distal embolic protection devices
5.2.6 Y-o-Y Growth Analysis, By Treatment devices
5.2.7 Market Attractiveness Analysis, By Treatment devices
5.2.8 Market Share Analysis, By Treatment devices
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Treatment Devices
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Application
6.1.4.3 By Treatment devices
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Application
6.1.5.3 By Treatmentr Devices
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Amgen Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Merck & Co., Inc.
8.3 Bristol-Myers Squibb Company
8.4 Hoffmann-La Roche Inc
8.5 Shire Inc.
8.6 Fresenius Medical Care
8.7 Baxter International
8.8 Davita Healthcare Partners
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
